

lines 29-34; page 12, lines 35-37; page 13, line 16 to page 14, line 24; page 21, lines 34 to page 22, line 17; page 48, lines 11-19; page 49, lines 28-30; and Figure 12, for example.

The new claims are drawn to methods of treatment, and Applicants believe that all new claims fall within provisionally elected Group IV. Like the claims of Group IV, the new claims relate to methods of treatment, comprising administering a therapeutically effective amount of a P-selectin ligand protein to a subject. Similarly, the protein to be administered in new claims 62-69, comprises amino acid 42 to amino acid 60 of SEQ ID NO:2. Applicants, thus, request that the new claims be examined with the claims of Group IV if the current restriction is maintained.

In view of the foregoing amendments and remarks, Applicants respectfully request examination of this application and the timely allowance of the pending claims.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 18, 2004

By: _____


Mary K. Ferguson
Reg. No. 51,675